Kuraray (OTCMKTS:KURRY) Shares Down 15.2% - Should You Sell?

Key Points

• Kuraray shares fell 15.2% during mid-day trading on Friday, with the stock last traded at $30.60, significantly lower than its previous close of $36.10.
• The company reported $0.04 earnings per share and $1.42 billion in revenue for the most recent quarter, with a net margin of 1.90%.
• Kuraray has a market capitalization of $3.31 billion and a low debt-to-equity ratio of 0.22, indicating a relatively strong financial position.

Kuraray Co. (OTCMKTS:KURRY - Get Free Report) dropped 15.2% during mid-day trading on Friday . The stock traded as low as $30.60 and last traded at $30.60. Approximately 824 shares traded hands during mid-day trading, an increase of 324% from the average daily volume of 195 shares. The stock had previously closed at $36.10.

Kuraray Trading Down 15.2%

The firm has a fifty day moving average of $34.92 and a 200-day moving average of $35.73. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.33 and a current ratio of 2.44. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of 31.22 and a beta of 0.06.

Kuraray (OTCMKTS:KURRY - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported $0.04 earnings per share for the quarter. The company had revenue of $1.42 billion during the quarter. Kuraray had a return on equity of 5.38% and a net margin of 1.90%.

Kuraray Company Profile

Kuraray Co, Ltd. engages in the production and sale of resins, chemicals, fibers, activated carbon, and high-performance membranes and systems worldwide. The Vinyl Acetate segment manufactures and markets functional resins and films, including PVA, PVB and EVAL. The Isoprene segment engages in the manufacture and marketing of SEPTON thermoplastic elastomer, isoprene-related products, and GENESTAR.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.